Skip to main content

Bacteriophages against multi-drug resistant bacteria

Guest Editors:
Reza Ghotaslou: Tabriz University of Medical Sciences, Iran
Gerald Mboowa: Africa Centers for Disease Control and Prevention, Ethiopia


BMC Infectious Diseases called for submissions to our Collection on Bacteriophages against multi-drug resistant bacteria.

Bacteriophages, or phages for short, are viruses that infect and kill bacteria. Bacteriophages have gained a lot of attention in recent years due to their potential as an alternative to antibiotics in the fight against multi-drug resistant bacteria.

In this Collection, we invited researchers and experts in the field of infectious diseases to contribute original research articles on the use of phages as a treatment for multi-drug resistant bacteria. We welcomed submissions that explore the mechanisms of phage-bacteria interactions, the development of phage therapy protocols, and the clinical applications of phage therapy in humans and animals.

Meet the Guest Editors

Back to top

Reza Ghotaslou: Tabriz University of Medical Sciences, Iran

Dr Reza Ghotaslou is a professor and full-time junior lecturer at the Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Dr. Ghotaslou has been an active researcher and academic in the field of Microbiology for more than 20 years and is a member of the Iranian Laboratory Sciences Association and editor advisor for several journals in the field of infectious diseases. His research interest include nosocomial infections, gut microbiota, and infectious diseases epidemiology.

Gerald Mboowa: Africa Centers for Disease Control and Prevention, Ethiopia

Dr Gerald Mboowa is a Bioinformatics Expert at the Africa Centers for Disease Control and Prevention, Ethiopia. He is passionate about the deployment of sequencing technologies in disease outbreak investigations, pathogen characterization as well antimicrobial resistance (AMR) surveillance. He has over time transitioned to applying bioinformatics tools to analyze genomic data generated from exploring different questions such as pathogen typing, genomic characterization, surveillance, virulence determinants, and decrypting AMR in drug-resistant Mycobacterium tuberculosis and other clinically important bacteria. His work also focuses on using genomic technologies and bioinformatics to track AMR to better understand genomic determinants of resistance and mechanisms.

About the collection

BMC Infectious Diseases is calling for submissions to our Collection on Bacteriophages against multi-drug resistant bacteria.

Bacteriophages, or phages for short, are viruses that infect and kill bacteria. Bacteriophages have gained a lot of attention in recent years due to their potential as an alternative to antibiotics in the fight against multi-drug resistant bacteria.

Bacterial resistance to antibiotics has become a major public health issue worldwide, leading to increased morbidity, mortality, and healthcare costs. Phages offer a promising solution to this problem, as they are highly specific to their bacterial host and can kill bacteria without harming the body's own cells.

It is crucial to continue advancing our collective understanding of bacteriophages' usefulness as a tool against multi-drug resistant bacteria because the problem of antibiotic resistance is not going away. Recent interdisciplinary research has revealed important insights into the mechanisms of phage-bacteria interactions and the design of effective phage therapy protocols. These advances have paved the way for the development of novel treatments that could save lives and reduce the burden of infectious diseases worldwide. Looking to the future, continued research into phage therapy could lead to even more breakthroughs, such as the creation of personalized phage therapies tailored to individual patients and the development of new methods for producing and delivering phages effectively.

In this Collection, we invite researchers and experts in the field of infectious diseases to contribute original research articles on the use of phages as a treatment for multi-drug resistant bacteria. We welcome submissions that explore the mechanisms of phage-bacteria interactions, the development of phage therapy protocols, and the clinical applications of phage therapy in humans and animals.

We encourage authors to submit high-quality, rigorous research that advances our understanding of phage biology and their potential as an alternative to antibiotics. The scope of this Collection includes but is not limited to:

  • Phage therapy for ESKAPE bacteria
  • Developing phage-based strategies to combat antimicrobial resistance
  • Understanding phage-microbiome interactions for improved therapy
  • The potential of lytic phages as a tool for fighting drug resistance
  • Phageome analysis for identification of novel phages for therapy
  • Bacteriophages as an antibiotic replacement in the antimicrobial crisis


Image credit: © iLexx / Getty Images / iStock

  1. Escherichia coli is a common fecal coliform, facultative aerobic, gram-negative bacterium. Pathogenic strains of such microbes have evolved to cause diarrhea, urinary tract infections, and septicemias. The emerg...

    Authors: Tamirat Salile Sada and Tesfaye Sisay Tessema
    Citation: BMC Infectious Diseases 2024 24:310
    Content type: Research Published on:

Submission Guidelines

Back to top

This Collection welcomes submission of original Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Bacteriophages against multi-drug resistant bacteria" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.